Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors

摘要: More than 40 years ago, we discovered that novel transplantation antigens can be induced in vivo or vitro by treating murine leukemia with dacarbazine. Years later, this phenomenon called "Chemical Xenogenization" (CX) and more recently, "Drug-Induced (DIX), was reproduced Thierry Boon a mutagenic/carcinogenic compound (i.e. N-methyl-N'-nitro-N-nitrosoguanidine). In both cases, the molecular bases of DIX rely on mutagenesis methyl adducts to oxygen-6 DNA guanine. present review illustrate main DIX-related immune-pharmacodynamic properties triazene compounds clinical use dacarbazine temozolomide).In recent years, tumor immunotherapy has come back stage discovery immune checkpoint inhibitors (ICpI) show an extraordinary immune-enhancing activity. Here salient biochemical features some most interesting ICpI up-to-day status their use. Moreover, literature showing direct relationship between somatic mutation burden susceptibility cancer cells host's responses.When discovered, were not able satisfactorily exploit possible presence triazene-induced neoantigens malignant since no device available adequately enhance responses settings. Today, unprecedented efficacy terms survival times, especially when elevated load is associated cells. Therefore, future, mutation-dependent obtained appropriate pharmacological intervention appear disclose approach for enhancing therapeutic patients.